摘要
目的:了解我院深静脉血栓患者华法林用药情况及存在的问题并提出建议,促进临床合理用药。方法:对2013年10月~2014年3月我院服用华法林治疗深静脉血栓的住院患者病历进行回顾性调查分析,调查内容包括在院期间华法林联合用药、用药期间国际标准化比值(INR)监测、华法林剂量调整等情况,并参照国内外指南进行综合评价和分析。结果:共收集62例患者病历,我院尚存在患者服用华法林期间联用药物种类多、INR监测不规范、华法林剂量调整不及时、住院期及出院前INR达标率低等问题。结论:目前我院华法林用药尚存在不足,需参照指南制定华法林用药规范,指导临床合理使用华法林进行抗凝治疗。
Objective:To investigate application of warfrain on deep venous thrombosis among our hospital, discover the existed problem and seek for solution, in order to promote the rational drug use. Methods:The inpatient cases between October 2013 to March 2014 diagnosed of deep venous thrombosis were collected, who were given warfrain for an- tithrombotie therapy. The drug combination, INR-monitoring and close adjustment of warfrain, base on the guideline at home and abroad were appraised. Results: A total of 62 cases were enrolled and appraised. It showed that patients in our hospital who were consuming warfrain turned to receive various kinds of medicine altogether. With irregular INR monitoring and delayed dose adjustment, most of the patients could not achieve the therapeutic range measured by INR. Conclusion: At the present, the application of warfrain in our hospital was undesirable. Medicine practice of warfrain needed to be for- mulated according to the available guideline. Under the instruction of the practive, we could anticipate that warfrain would be used more rationally.
出处
《药物流行病学杂志》
CAS
2015年第9期547-550,共4页
Chinese Journal of Pharmacoepidemiology